Table 3. ES PDX models: response to treatment (day 21).
| PDX Model | Treatment | Tumors (n) | Response1 | |||
|---|---|---|---|---|---|---|
| CR | PR | SD | PD | |||
| HSJD-ES-004 | Control | 10 | 0 | 0 | 0 | 10 |
| Olaparib | 9 | 0 | 0 | 0 | 9 | |
| Trabectedin | 8 | 7 | 0 | 0 | 1 | |
| Combination | 8 | 8 | 0 | 0 | 0 | |
| HSJD-ES-006 | Control | 10 | 0 | 0 | 0 | 10 |
| Olaparib | 10 | 0 | 0 | 0 | 10 | |
| Trabectedin | 9 | 1 | 1 | 0 | 7 | |
| Combination | 9 | 9 | 0 | 0 | 0 | |
1
CR: Complete response (CR) was defined, as previously described in [34], as the disappearance of measurable tumor mass (<0.10 cm3) at the end of treatment (day 21); PR: Partial response (PR) was defined as a tumor volume regression ≥50% at the end of treatment (day 21) but with a measurable tumor size (≥0.10 cm3); SD: Stable disease (SD) was defined as <50% regression from the initial volume and a ≤25% increase in initial volume at the end of treatment (day 21). PD: Progressive disease (PD) was defined as <50% regression from the initial volume and a >25% increase in the initial volume at the end of treatment (day 21).